托法替尼用于克罗恩病诱导和维持治疗:两项IIb期随机安慰剂对照试验结果
两项随机双盲安慰剂对照多中心IIb期研究评估口服托法替尼治疗中重度克罗恩病的疗效与安全性。诱导治疗8周后,托法替尼5 mg和10 mg每日两次组临床缓解率分别为43.5%和43.0%,安慰剂组为36.7%,差异无统计学显著性;维持治疗26周,托法替尼10 mg每日两次组临床应答-100或缓解率为55.8%,5 mg组为39.5%,安慰剂组为38.1%,与安慰剂比较差异无统计学显著性。主要疗效终点与安慰剂无显著差异,但可见轻微治疗效应证据,未观察到新的安全性信号。
要点
- 诱导治疗8周,托法替尼5 mg和10 mg每日两次组临床缓解率分别为43.5%和43.0%,安慰剂组36.7%,差异无统计学显著性。
- 维持治疗26周,托法替尼10 mg每日两次组临床应答-100或缓解率55.8%,5 mg组39.5%,安慰剂组38.1%,与安慰剂比较差异无统计学显著性。
- 与安慰剂相比,托法替尼10 mg每日两次组C反应蛋白自基线变化在诱导和维持治疗后均具有统计学显著性(p<0.0001)。
核心结论
- 主要疗效终点与安慰剂无显著差异,但存在轻微治疗效应的证据;未观察到托法替尼新的安全性信号。
研究设计与样本
- 两项随机、双盲、安慰剂对照、多中心IIb期研究。
- 中重度克罗恩病成人患者随机接受安慰剂、托法替尼5 mg或10 mg每日两次诱导治疗8周。
- 达到临床应答-100或缓解者再随机接受安慰剂、托法替尼5 mg或10 mg每日两次维持治疗26周。
- 诱导研究随机280例,其中180例纳入维持研究。
主要发现
- 诱导治疗第8周,托法替尼5 mg和10 mg每日两次组临床缓解率分别为43.5%和43.0%,安慰剂组为36.7%(5 mg组vs安慰剂p=0.325,10 mg组vs安慰剂p=0.392)。
- 维持治疗第26周,托法替尼10 mg每日两次组临床应答-100或缓解率为55.8%,托法替尼5 mg每日两次组为39.5%,安慰剂组为38.1%(10 mg组vs安慰剂p=0.130)。
- 与安慰剂相比,托法替尼10 mg每日两次组C反应蛋白自基线变化在诱导和维持治疗后均具有统计学显著性(p<0.0001)。
局限性
- 主要疗效终点与安慰剂无显著差异,但存在轻微治疗效应证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tofacitinib is an oral, small-molecule Janus kinase inhibitor that is being investigated for IBD. We evaluated the efficacy and safety of tofacitinib for induction and maintenance treatment in patients with moderate-to-severe Crohn's disease (CD). DESIGN: We conducted two randomised, double-blind, placebo-controlled, multicentre phase IIb studies. Adult patients with moderate-to-severe CD were randomised to receive induction treatment with placebo, tofacitinib 5 or 10 mg twice daily for 8 weeks. Those achieving clinical response-100 or remission were re-randomised to maintenance treatment with placebo, tofacitinib 5 or 10 mg twice daily for 26 weeks. Primary endpoints were clinical remission at the end of the induction study, and clinical response-100 or remission at the end of the maintenance study. RESULTS: 180/280 patients randomised in the induction study were enrolled in the maintenance study. At week 8 of induction, the proportion of patients with clinical remission was 43.5% and 43.0% with 5 and 10 mg twice daily, respectively, compared with 36.7% in the placebo group (p=0.325 and 0.392 for 5 and 10 mg twice daily vs placebo). At week 26 of maintenance, the proportion of patients with clinical response-100 or remission was 55.8% with tofacitinib 10 mg twice daily compared with 39.5% with tofacitinib 5 mg twice daily and 38.1% with placebo (p=0.130 for 10 mg twice daily vs placebo). Compared with placebo, the change in C-reactive protein from baseline was statistically significant (p<0.0001) with 10 mg twice daily after both induction and maintenance treatments. CONCLUSIONS: Primary efficacy endpoints were not significantly different from placebo, although there was evidence of a minor treatment effect. No new safety signals were observed for tofacitinib. TRIAL REGISTRATION NUMBERS: NCT01393626 and NCT01393899.
引用
- Panés J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017. PMID: 28209624. doi:10.1136/gutjnl-2016-312735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。